Vertex Pharmaceuticals’ New Drugs Are Gaining Ground. Is That Enough for Investors?

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has spent years building a highly profitable cystic fibrosis franchise. Now, with newer treatments entering the market and its acquisition of Crinetics Pharmaceuticals completed, the company is working to establish additional sources of growth. The stock closed at $510.08 on October 9, with a forward P/E of 24.10, according to the […]